Axsome Therapeutics (NASDAQ:AXSM) Given Outperform Rating at Royal Bank of Canada

Royal Bank of Canada reaffirmed their outperform rating on shares of Axsome Therapeutics (NASDAQ:AXSM) in a report published on Wednesday morning,Benzinga reports. They currently have a $139.00 target price on the stock.

A number of other research firms have also weighed in on AXSM. HC Wainwright reissued a “buy” rating and issued a $180.00 target price on shares of Axsome Therapeutics in a research note on Tuesday, January 21st. William Blair reiterated an “outperform” rating on shares of Axsome Therapeutics in a research report on Friday, January 24th. Mizuho dropped their target price on Axsome Therapeutics from $124.00 to $122.00 and set an “outperform” rating for the company in a report on Tuesday, December 31st. StockNews.com upgraded Axsome Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. Finally, Truist Financial upped their price objective on shares of Axsome Therapeutics from $150.00 to $180.00 and gave the company a “buy” rating in a report on Monday, January 13th. One investment analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $132.08.

Axsome Therapeutics Stock Down 2.2 %

NASDAQ AXSM opened at $106.46 on Wednesday. Axsome Therapeutics has a one year low of $64.11 and a one year high of $111.51. The company has a debt-to-equity ratio of 1.97, a quick ratio of 2.37 and a current ratio of 2.44. The business has a fifty day moving average price of $93.57 and a 200 day moving average price of $90.81. The company has a market cap of $5.16 billion, a P/E ratio of -16.30 and a beta of 1.04.

Axsome Therapeutics (NASDAQ:AXSM) last issued its earnings results on Tuesday, November 12th. The company reported ($1.34) EPS for the quarter, beating analysts’ consensus estimates of ($1.38) by $0.04. The business had revenue of $104.76 million during the quarter, compared to analysts’ expectations of $98.71 million. Axsome Therapeutics had a negative net margin of 91.87% and a negative return on equity of 158.36%. During the same period in the prior year, the business earned ($1.32) earnings per share. Research analysts anticipate that Axsome Therapeutics will post -4.72 EPS for the current fiscal year.

Institutional Trading of Axsome Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Northwestern Mutual Wealth Management Co. acquired a new position in Axsome Therapeutics during the second quarter worth $27,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Axsome Therapeutics in the 2nd quarter valued at $47,000. R Squared Ltd acquired a new position in Axsome Therapeutics during the 4th quarter worth about $64,000. KBC Group NV boosted its holdings in Axsome Therapeutics by 40.5% during the 4th quarter. KBC Group NV now owns 1,336 shares of the company’s stock valued at $113,000 after acquiring an additional 385 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in Axsome Therapeutics by 22.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,736 shares of the company’s stock valued at $156,000 after acquiring an additional 318 shares in the last quarter. Institutional investors and hedge funds own 81.49% of the company’s stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.